A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.

ABSTRACT: Lung squamous cell carcinoma (LUSC) comprises 20-30% of all lung cancers. Immunotherapy has significantly improved the prognosis of LUSC patients; however, only a small subset of patients responds to the treatment. Therefore, we aimed to develop a novel multi-gene signature associated with the immune phenotype of the tumor microenvironment for LUSC prognosis prediction. We stratified the LUSC patients from The Cancer Genome Atlas dataset into hot and cold tumor according to a combination of infiltration status of immune cells and PD-L1 expression level. Kaplan-Meier analysis showed that hot tumors were associated with shorter overall survival (OS). Enrichment analyses of differentially expressed genes (DEGs) between the hot and cold tumors suggested that hot tumors potentially have a highe

SUBMITTER: Yang Q 

PROVIDER: S-EPMC9372044 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature